NASDAQ:HOOK HOOKIPA Pharma (HOOK) Stock Price, News & Analysis $1.15 0.00 (0.00%) As of 06/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock About HOOKIPA Pharma Stock (NASDAQ:HOOK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HOOKIPA Pharma alerts:Sign Up Key Stats Today's Range$1.11▼$1.1550-Day Range$1.09▼$1.1952-Week Range$0.81▼$1.65Volume431 shsAverage Volume11,089 shsMarket Capitalization$14.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview HOOKIPA Pharma Inc. is a clinical-stage biotechnology company focused on the development of virus-based immunotherapies and vaccines. The company operates two complementary platform technologies—an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system—designed to stimulate both humoral and cellular immune responses. By combining these platforms, HOOKIPA aims to address infectious diseases and drive novel immuno-oncology treatments. In the infectious disease arena, HOOKIPA’s pipeline includes prophylactic vaccine candidates targeting pathogens such as cytomegalovirus (CMV) in transplant settings and other viral threats. The arenavirus-based platform is leveraged to induce strong T-cell responses against persistent viruses, while the MVA vector is optimized for broader antibody and T-cell activation. Preclinical and early clinical data have underscored the potential of these approaches to provide durable immunity with a favorable safety profile. Beyond infectious disease, HOOKIPA is advancing immuno-oncology programs that employ its vector systems to generate anti-tumor immune responses. These candidates are engineered to present tumor-associated antigens, aiming to recruit and expand cytotoxic T cells within the tumor microenvironment. This dual focus on both prophylactic and therapeutic indications reflects the company’s strategy to harness its platform versatility across multiple disease areas. Founded in 2016, HOOKIPA Pharma is headquartered in Vienna, Austria, with a U.S. subsidiary based in New York. The company’s leadership team comprises experienced executives and scientific founders who have previously held senior roles in biopharmaceutical research and development. HOOKIPA continues to collaborate with academic institutions and industry partners to advance its clinical pipeline and expand the reach of its novel immunotherapy platforms.AI Generated. May Contain Errors. Read More Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HOOKIPA Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HOOK Stock News HeadlinesHOOKIPA PharmaApril 6, 2026 | fool.comHOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail TherapeuticsMarch 27, 2026 | markets.businessinsider.comIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.June 12 at 1:00 AM | InvestPub (Ad)HOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail TherapeuticsFebruary 3, 2026 | quiverquant.comQHOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail TherapeuticsFebruary 3, 2026 | globenewswire.comHOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead SciencesOctober 31, 2025 | quiverquant.comQHOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to GileadOctober 31, 2025 | globenewswire.comHOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead SciencesJuly 18, 2025 | quiverquant.comQSee More Headlines HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? HOOKIPA Pharma's stock was trading at $0.8965 at the beginning of the year. Since then, HOOK shares have increased by 28.3% and is now trading at $1.15. How were HOOKIPA Pharma's earnings last quarter? HOOKIPA Pharma Inc. (NASDAQ:HOOK) announced its earnings results on Thursday, May, 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by $0.62. HOOKIPA Pharma had a negative trailing twelve-month return on equity of 120.09% and a negative net margin of 785.66%. When did HOOKIPA Pharma's stock split? HOOKIPA Pharma shares reverse split on the morning of Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did HOOKIPA Pharma IPO? HOOKIPA Pharma (HOOK) raised $90 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of HOOKIPA Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HOOKIPA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/15/2025Today6/12/2026Next Earnings (Estimated)8/07/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOOK CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees160Year Founded2011Profitability EPS (Trailing Twelve Months)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.50 million Net Margins-785.66% Pretax Margin-785.15% Return on Equity-120.09% Return on Assets-77.14% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual Sales$9.35 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.27Miscellaneous Outstanding Shares12,330,000Free Float11,787,000Market Cap$14.18 million OptionableOptionable Beta0.85 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:HOOK) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles, link...Smallcaps Daily | SponsoredVWAV: Is This the Next Defense Breakout?VisionWave Holdings, Inc. (NASDAQ: VWAV) is developing a full-stack defense technology platform that integrate...Equiscreen | SponsoredPhysical gold in your 401k - what Wall Street already knowsOn March 30th, the Department of Labor quietly filed a rule allowing physical gold to be held inside an eligib...Cedar Gold Group | SponsoredThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...Priority Gold | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HOOKIPA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HOOKIPA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOOK Stock Alerts